Proportion patients in sustained disease remission 1 year [clinicaltrials_resource:7e26ad3e87eaa1f58d1aa312ca726b3a]
To evaluate the potential clinical benefit of hematopoietic stem cell mobilisation followed by high dose immuno-ablation and autologous stem cell transplantation versus hematopoietic stem cell mobilisation only followed by best clinical practice in patients with Crohn' s disease.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Proportion patients in sustained disease remission 1 year [clinicaltrials_resource:7e26ad3e87eaa1f58d1aa312ca726b3a]
To evaluate the potential clinical benefit of hematopoietic stem cell mobilisation followed by high dose immuno-ablation and autologous stem cell transplantation versus hematopoietic stem cell mobilisation only followed by best clinical practice in patients with Crohn' s disease.
Bio2RDF identifier
7e26ad3e87eaa1f58d1aa312ca726b3a
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:7e26ad3e87eaa1f58d1aa312ca726b3a
measure [clinicaltrials_vocabulary:measure]
Proportion patients in sustained disease remission
time frame [clinicaltrials_vocabulary:time-frame]
description
To evaluate the potential clin ...... atients with Crohn' s disease.
identifier
clinicaltrials_resource:7e26ad3e87eaa1f58d1aa312ca726b3a
title
Proportion patients in sustained disease remission 1 year
@en
type
label
Proportion patients in sustain ...... 6ad3e87eaa1f58d1aa312ca726b3a]
@en